Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 550 of 2051 entries
View as:

Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)

Phase: N/A Priority: Normal
NCT ID: NCT00806585 Org: User:
Start: 12/31/08 End: 06/30/10 Due: 06/30/11

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Phase: N/A Priority: Normal
NCT ID: NCT04246177 Org: User:
Start: 05/22/20 End: 12/31/29 Due: 12/31/30

A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC

Phase: N/A Priority: Normal
NCT ID: NCT00002155 Org: User:
Start: - End: - Due: -

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

Phase: N/A Priority: Normal
NCT ID: NCT04644029 Org: User:
Start: 02/24/21 End: 06/11/24 Due: 06/11/25

A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)

Phase: N/A Priority: Normal
NCT ID: NCT05818137 Org: User:
Start: 05/10/23 End: 02/27/26 Due: 02/27/27

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Phase: N/A Priority: Normal
NCT ID: NCT06136624 Org: User:
Start: 12/31/23 End: 08/02/28 Due: 08/02/29

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Phase: N/A Priority: Normal
NCT ID: NCT03725059 Org: User:
Start: 12/27/18 End: 01/24/31 Due: 01/24/32

Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)

Phase: N/A Priority: Normal
NCT ID: NCT01986881 Org: User:
Start: 11/04/13 End: 12/27/19 Due: 12/27/20

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

Phase: N/A Priority: Normal
NCT ID: NCT06132958 Org: User:
Start: 12/06/23 End: 01/10/28 Due: 01/10/29

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

Phase: N/A Priority: Normal
NCT ID: NCT03182907 Org: User:
Start: 03/27/18 End: 05/12/22 Due: 05/12/23

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Phase: N/A Priority: Normal
NCT ID: NCT00773747 Org: User:
Start: 12/01/08 End: 06/30/15 Due: 06/30/16

Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)

Phase: N/A Priority: Normal
NCT ID: NCT00128115 Org: User:
Start: 09/30/05 End: 08/31/07 Due: 08/31/08

Fenofibrate Bioequivalence Study (0767-031)

Phase: N/A Priority: Normal
NCT ID: NCT00928694 Org: User:
Start: 02/28/03 End: 04/30/04 Due: 04/30/05

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)

Phase: N/A Priority: Normal
NCT ID: NCT01254630 Org: User:
Start: 06/24/11 End: 04/11/17 Due: 04/11/18

Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)

Phase: N/A Priority: Normal
NCT ID: NCT02629822 Org: User:
Start: 01/14/16 End: 10/28/20 Due: 10/28/21

Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)

Phase: N/A Priority: Normal
NCT ID: NCT01014013 Org: User:
Start: 04/30/08 End: 02/28/09 Due: 02/28/10

Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00787371 Org: User:
Start: 06/30/05 End: 07/31/06 Due: 07/31/07

Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00160251 Org: User:
Start: 09/30/05 End: 07/31/07 Due: 07/31/08

Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)

Phase: N/A Priority: Normal
NCT ID: NCT00496054 Org: User:
Start: 05/31/08 End: 10/31/08 Due: 10/31/09

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)

Phase: N/A Priority: Normal
NCT ID: NCT00105469 Org: User:
Start: 07/31/04 End: 10/31/05 Due: 10/31/06

Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)

Phase: N/A Priority: Normal
NCT ID: NCT00083343 Org: User:
Start: 05/31/04 End: 02/28/06 Due: 02/28/07

Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00804843 Org: User:
Start: 04/30/09 End: 10/31/10 Due: 10/31/11

Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

Phase: N/A Priority: Normal
NCT ID: NCT01337167 Org: User:
Start: 04/19/11 End: 05/09/13 Due: 05/09/14

A Study to Evaluate Biomarkers in Patients With Solid Tumors (0000-097)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00800865 Org: User:
Start: 01/31/09 End: 10/31/09 Due: 10/31/10

Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)

Phase: N/A Priority: Normal
NCT ID: NCT00255034 Org: User:
Start: 02/28/05 End: 06/30/08 Due: 06/30/09